Document Detail


Lipid levels after acute coronary syndromes.
MedLine Citation:
PMID:  18402897     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This analysis from the LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvastatin) study assessed lipid changes 1 to 4 days after onset of acute coronary syndromes (ACS), before initiation of study treatment. BACKGROUND: Early studies indicated that cholesterol levels decrease significantly after ACS. However, most studies were small or did not measure low-density lipoprotein cholesterol (LDL-C) directly, and many used nonfasting or retrospective data. More recent studies suggest less pronounced changes in cholesterol levels after ACS. METHODS: The LUNAR trial is a prospective, multicenter, randomized, open-label study in adults hospitalized for acute ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina (UA). Blood samples were taken at median times after onset of ACS symptoms of 26 h (Day 1, fasting or nonfasting sample), 43 h (Day 2, fasting sample), and 84 h (Day 4, fasting sample) for direct measurement of serum lipid levels before study treatments were started. RESULTS: Of 507 patients available for analysis, 212 were admitted for STEMI, 176 for non-STEMI, and 119 for UA. The LDL-C levels decreased in the 24 h after admission (from 136.2 to 133.5 mg/dl), followed by an increase over the subsequent 2 days (to 141.8 mg/dl). These changes did not seem to be clinically meaningful. Similar changes were observed for total cholesterol and smaller changes for high-density lipoprotein cholesterol; fasting triglyceride levels did not change. CONCLUSIONS: Mean lipid levels vary relatively little in the 4 days after an ACS and can be used to guide selection of lipid-lowering medication.
Authors:
Bertram Pitt; Joseph Loscalzo; Joseph Ycas; Joel S Raichlen
Related Documents :
2507877 - Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambula...
6956267 - Responses of serum lipoproteins to dietary cholesterol and type of fat in the baboon.
8746877 - Intrauterine administration of levonorgestrel in two low doses in hrt. a randomized cli...
9192227 - The relationship between weight and response to cholesterol-lowering diets in women.
7860947 - Problems encountered in meeting the recommended dietary allowances for menus designed a...
19363037 - Regulation of intracellular cholesterol distribution by na/k-atpase.
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  51     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-04-11     Completed Date:  2008-05-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1440-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA. bpitt@med.umich.edu
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00214630
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / blood*,  drug therapy,  physiopathology
Adolescent
Adult
Aged
Angina, Unstable / blood
Anticholesteremic Agents / therapeutic use
Cholesterol, LDL / drug effects*
Female
Fluorobenzenes / therapeutic use
Heart Conduction System / physiopathology*
Heptanoic Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Middle Aged
Myocardial Infarction / blood
Prognosis
Prospective Studies
Pyrimidines / therapeutic use
Pyrroles / therapeutic use
Randomized Controlled Trials as Topic
Sulfonamides / therapeutic use
Time Factors
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Pyrroles; 0/Sulfonamides; 0/Triglycerides; 110862-48-1/atorvastatin; 287714-41-4/rosuvastatin
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2008 Apr 15;51(15):1446-7   [PMID:  18402898 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute ...
Next Document:  Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidne...